Skip to main content
. 2015 Jul 6;10(7):e0131569. doi: 10.1371/journal.pone.0131569

Fig 3. PLS-DA analytical results from urine samples of BCCAO rats treated with Scu (A) or Scue (B) at six therapeutic cycles in positive mode.

Fig 3

C, sham-operated group (0–12 h); M, model group (0–12 h); Scu 1–6, after administration of Scu for 0–12 h (Scu1), 12–24 h (Scu2), 24–36 h (Scu3), 36–48 h (Scu4), 48h-60 h (Scu5) and 60–72 h (Scu6); Scue 1–6, after administration of Scue for 0–12 h (Scue1), 12–24 h (Scue2), 24–36 h (Scue3), 36–48 h (Scue4), 48h-60 h (Scue5) and 60–72 h (Scue6). PLS-DA analytical results from BCCAO rat urine samples treated with Scu, Scue, and nimodipine at 12–24 h in positive (C) and negative modes (D). C, sham-operated group; M, model group; Scu, after administration of Scu; Scue, after administration of Scue; N, after administration of nimodipine.